Pegylated liposomal doxorubicin plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian cancer (CGCS-04): a multicenter, randomized clinical trial
Authors
Mei Ling Pan (ORCID: https://orcid.org/0000-0002-8979-7305)
Pegylated liposomal doxorubicin plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian cancer (CGCS-04): a multicenter, randomized clinical trial
Mei Ling Pan, Xianghua Huang, Yumin Meng, Ying Yue et al.
Journal
Therapeutic Advances in Medical Oncology
Topics
Ovarian cancer diagnosis and treatment
article
Pegylated liposomal doxorubicin plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian cancer (CGCS-04): a multicenter, randomized clinical trial
Hebei Medical University (CN), Guiyang Medical University (CN), Harbin Medical University (CN), Sichuan University (CN), Tianjin Medical University Cancer Institute and Hospital (CN), Chinese PLA General Hospital (CN), West China Second University Hospital of Sichuan University (CN), Second Hospital of Hebei Medical University (CN), Shandong Tumor Hospital (CN), Guizhou Cancer Hospital (CN), Third Affiliated Hospital of Harbin Medical University (CN), Fourth Hospital of Hebei Medical University (CN), Jiangxi Maternal and Child Health Hospital (CN), Affiliated Hospital of Guizhou Medical University (CN), Hebei General Hospital (CN), Shandong Provincial Hospital (CN), Tianjin Central Hospital of Gynecology Obstetrics (CN), Wuhan Union Hospital (CN), Anhui Provincial Hospital (CN), Women's Hospital, School of Medicine, Zhejiang University (CN), First Bethune Hospital of Jilin University (CN), Jiangsu Province Hospital (CN), First Affiliated Hospital of Zhengzhou University (CN), Tongji Hospital (CN), Qilu Hospital of Shandong University (CN), Shandong First Medical University (CN), Huazhong University of Science and Technology (CN)